An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.

Blood
Paul J MartinStephanie J Lee

Abstract

No gold standard has been established as a primary endpoint in trials of initial treatment of chronic graft-versus-host disease (GVHD), and evidence showing the association of any proposed primary endpoint with clinical benefit has not been conclusively demonstrated. To address this gap, we analyzed outcomes in a cohort of 328 patients enrolled in a prospective, multicenter, observational study within 3 months after diagnosis of chronic GVHD. Complete and partial response, stable disease, and progressive disease were defined according to the 2014 National Institutes of Health Consensus Development Conference on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease. Success was defined as complete or partial response with no secondary systemic treatment or recurrent malignancy at 1 year after enrollment. Success was observed in fewer than 20% of the patients. The burden of disease manifestations at 1 year was lower for patients in this category than for those with stable or progressive disease. Systemic treatment ended earlier, and subsequent mortality was lower among patients with complete or partial response than among those with stable or progressive disease and those who had received secondary systemic treatment....Continue Reading

Associated Clinical Trials

References

Feb 27, 2001·Blood·G B Vogelsang
Sep 18, 2002·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Stephanie k LeeJoseph H Antin
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
May 28, 2009·Blood·Afonso C VigoritoUNKNOWN National Institutes of Health
Jun 15, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·UNKNOWN Chronic GVHD Consortium
Apr 16, 2013·Bone Marrow Transplantation·L F NewellC Delaney
Jun 11, 2014·Blood·Gérard Socié, Jerome Ritz
Nov 16, 2014·Blood·Mary E D Flowers, Paul J Martin
May 20, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Paul J MartinCorey S Cutler

❮ Previous
Next ❯

Citations

Nov 25, 2017·Blood·Hildegard T Greinix
Jan 25, 2019·Blood·Stefanie SarantopoulosKeith M Sullivan
Oct 4, 2019·Nature Communications·Naoya UchidaJohn F Tisdale
Feb 27, 2020·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Bellinda L King-KallimanisPaul G Kluetz
Oct 5, 2018·JCI Insight·Jonathan C PoeStefanie Sarantopoulos
Aug 24, 2018·Molecular Medicine·Andrea ZivotLionel Blanc
Jul 22, 2017·Blood·Nicolaus Kröger
Feb 20, 2020·Stem Cell Research & Therapy·Cynthia Morata-TarifaRosario Sanchez-Pernaute
Jan 29, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ran ReshefJohn E Levine
Sep 12, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Badri ModiRyotaro Nakamura
Apr 21, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Madan JagasiaStephanie J Lee
Jul 15, 2021·The New England Journal of Medicine·Robert ZeiserUNKNOWN REACH3 Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.